This week we’re focusing on MASH. It’s a high area of unmet medical need, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development. 25 June 2024
At the AAIC in Amsterdam, we’re speaking with two key figures from Lilly's development program for donanemab, as the company presents new data that could help i 17 July 2023
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress 6 July 2023
Flagship Pioneering has had an outsized impact on the sector, launching a spate of successful biotechs, including Moderna Therapeutics. Now, with Pioneering Med 20 April 2023
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biot 2 February 2023
The outcome of the recent mid-term elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the ne 28 November 2022
As President Joe Biden signs the Inflation Reduction Act into law.drugmakers in the USA are poring over the likely impact on drug prices.and how best to respond 17 August 2022
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government ac 22 July 2022
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsew 4 July 2022
In recent years there has been an explosion of digital tools in the life sciences.but as with everything in pharma and biotech.their value hinges on the strengt 5 April 2022
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the approach. James McIlroy, 9 March 2022
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription 4 March 2022
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement 10 February 2022
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episo 30 December 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.